bioavailability enhancement techniques

The depth of our bioavailability (BA) enhancement offering makes us a leader in addressing low solubility, low bioavailability and dissolution rate issues. We work collaboratively with our customers to advance compounds, or re-purpose existing compounds, across a full range of API properties and delivery challenges. Our end-to-end enhancement solutions incorporate full capabilities in bringing a compound from concept to commercialization, thereby minimizing program complexity, timelines and risk.

Industry estimates indicate that more than 80% of new chemical entities exhibit low solubility, low bioavailability and / or low or inconsistent dissolution rate. Effectively addressing these drug solubility, bioavailability and dissolution rate problems is essential for advancing the compound and providing the desired therapeutic benefit of the drug product to patient. And ensuring that the solubility solution incorporates the ultimate manufacturability of the drug product can avoid time-consuming re-formulation and ensure rapid advancement to market.

We recognize the core challenges of advancing the new chemical compounds in today’s biopharmaceutical pipeline. That’s why we have developed a portfolio of bioavailability enhancement technologies and services with which to address poor solubility and inadequate or inconsistent dissolution rate.

Our commitment to our customers includes a 30+ year track record across our fit-for-purpose bioavailability enhancement techniques with phase-appropriate processing in place to support non-GMP feasibility assessments through GMP clinical trials and commercial-scale manufacturing.

Want to learn about some of the most common bioavailability enhancing technologies for poorly soluble compounds?